Information Provided By: 
Fly News Breaks for January 8, 2020
HALO
Jan 8, 2020 | 05:24 EDT
Goldman Sachs analyst Graig Suvannavejh initiated coverage of Halozyme Therapeutics with a Buy rating and $24 price target. target. Given a recent Phase 3 proprietary asset failure, Halozyme is in the midst of reinventing itself, Suvannavejh tells investors in a research note. The analyst favors Halozyme, finding it not only a low risk approach to gain exposure to high growth prospects of the biotech sector.
News For HALO From the Last 2 Days
There are no results for your query HALO
